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Classification was validated with a sensitivity of 93 % and 
a specificity of 100 % (AUC of 98 %), and the results were 
compared with carbohydrate antigen 19-9 levels and cur-
rently available clinical imaging techniques. The ten most 
discriminating peptide peaks were identified as fragments 
of proteins involved in the clotting cascade, acute phase 
response and immunologic response.
Conclusions In this study, it is shown that MS-based 
serum peptide profiles can discriminate between PC and 
control samples. The approach has great potential for high-
throughput analysis in surveillance programs and appears 
to be most promising for patients with an inherited risk for 
PC, who benefit from more frequent screening.
Keywords Screening · MALDI-TOF · Biomarker 
signature · Proteomics · Clinical decision making
Introduction
In developed countries, pancreatic cancer (PC) has an 
annual incidence of 8.2 cases per 100,000 males and of 5.4 
cases per 100,000 females and is the fifth (male) and fourth 
(female) leading cause of cancer death (Jemal et al. 2011). 
Patients with PC have an extremely poor prognosis with 
an overall 5-year survival rate of <5 % (Siegel et al. 2011). 
After surgical resection, 5-year survival rates are approxi-
mately 25 % for node-negative and 10 % for node-positive 
tumors. However, upon diagnosis, most tumors (80 %) are 
in advanced stage (Sener et al. 1999). There is an urgent 
need for new strategies that aid in diagnosis for accurate 
clinical decision making and for use in surveillance pro-
grams. Currently, for diagnosis and staging, imaging tech-
niques such as computed tomography (CT) scan, mag-
netic resonance imaging (MRI) and magnetic resonance 
Abstract 
Purpose The detection of pancreatic tumors lacks a sensi-
tive and specific diagnostic tool. Mass spectrometry (MS)-
based profiling of serum proteins is a promising approach 
for discovery of new clinical biomarkers or biomarker 
signatures.
Methods Serum samples from pancreatic cancer (PC) 
patients and control individuals were collected and pro-
cessed using a standardized protocol. Samples were 
divided in a calibration set (n = 49 PC and 110 controls) 
and a validation set (n = 39 PC and 75 controls). Peptide 
profiles were obtained using a combination of automated 
solid-phase extraction with reversed-phase C18 paramag-
netic beads and matrix-assisted laser desorption ionization 
time-of-flight MS.
Results Linear discriminant analysis with double cross-
validation resulted in a discriminating peptide signature for 
PC in the calibration set with a sensitivity of 78 % and a 
specificity of 91 % [area under the curve (AUC) of 92 %]. 
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cholangiopancreatography (MRCP), positron emission 
tomography (PET) scan and endoscopic ultrasound (EUS) 
are available. Reported sensitivities and specificities for 
CT scan are 91 and 85 %, for MRI 84 and 82 %, respec-
tively, and for EUS sensitivity values of up to 100 % have 
been reported (Bipat et al. 2005; Dewitt et al. 2006). A CT 
scan is significantly better than MRI in the detection of PC, 
but there are no differences for both methods regarding 
their performance in staging and detection of metastases 
(Bipat et al. 2005). The choice for a CT scan or MRI often 
depends on the level of locally available expertise and may 
therefore vary. Multiple studies have compared EUS with 
other imaging modalities for initial diagnosis and stag-
ing of PC. In a systematic overview of EUS-based studies 
performed by Dewitt and co-workers, a pooled sensitivity 
(85 %) and specificity (94 %) were determined, and found 
to be similar to CT scan results (Dewitt et al. 2006). EUS 
is a more accurate device for local T (small tumors <2 cm) 
and N staging and for predicting vascular invasion, while a 
CT scan is preferred in the evaluation of distant metastasis. 
EUS-guided fine-needle aspiration biopsy (FNA) is the best 
modality, with a low chance of tumor-seeding, for obtain-
ing a conclusive diagnosis when the tumor seems irresect-
able or when neo-adjuvant therapy is planned (Micames 
et al. 2003). PET scanning with the tracer 18-fluorode-
oxyglucose (FDG) relies upon functional activity to dif-
ferentiate metabolically active proliferative lesions such as 
cancers from benign masses, most of which do not accu-
mulate FDG with the exception of inflammatory lesions 
such as chronic pancreatitis. A meta-analysis described 
the diagnostic value of the PET scan in case of a positive 
(sensitivity 92 %, specificity 68 %), negative (sensitiv-
ity 73 %, specificity 86 %) and non-conclusive (sensitiv-
ity 100 %, specificity 68 %) result of the CT scan (Orlando 
et al. 2004). In summary, a PET scan could be of additional 
value in the differential diagnosis of PC, but until now this 
is only be performed on an individual base. Chronic pan-
creatitis could imitate PC at diagnostics and hinders patient 
selection for a pancreaticoduodenectomy.
Major risk factors for developing PC include smoking, 
diabetes, chronic pancreatitis and hereditary predisposi-
tion (carriers of a p16-Leiden mutation, Peutz-Jeghers 
syndrome, familial atypical multiple mole melanoma 
(FAMMM) of BRCA2 mutation carriers) (Lynch et al. 
2009; Vasen et al. 2000). At this moment, screening of 
such a group with elevated risk factors is performed annu-
ally with MRI (Vasen et al. 2011). Furthermore, carbo-
hydrate antigen 19-9 (CA 19-9) is commonly used as a 
clinical biomarker in assisting differential diagnosis and 
monitoring of patients with PC. For monitoring purposes, 
this commercially available immunoassay-based test 
using the monoclonal antibody 1116-NS-19-9 has a sen-
sitivity of 70–87 % (Hansson and Zopf 1985). However, 
CA19-9 analysis is not optimal for the detection of small, 
resectable cancers and only recommended for follow-up 
(Goonetilleke and Siriwardena 2007). A more sensitive 
and specific option could be the use of serum protein 
biomarkers. By comparing peptide- or protein patterns, 
i.e., signatures, in serum from cancer patients with those 
obtained from control individuals, proteins that are most 
discriminating can be determined. The resulting peptide- 
or protein signature has the potential to identify a per-
son with cancer. Mass spectrometry (MS) is the method 
of choice for such an analysis of peptides and proteins in 
serum (Aebersold and Mann 2003). Previously, we have 
described discriminating serum protein profiles of PC 
patients obtained from weak-cation exchange paramag-
netic bead (MB) fractionation followed by matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) 
MS (Velstra et al. 2013). Since human body fluids (e.g., 
serum) are highly complex mixtures of salts, metabolites, 
lipids, peptides and proteins, these require a reproduc-
ible and robust “clean-up” procedure before MS analy-
sis (Aebersold and Mann 2003; Albrethsen 2007; Hortin 
2006). Often this clean-up is performed by solid-phase 
extraction (SPE), and to this end, functionalized MBs 
allow for selective enrichment of subsets of peptides and 
proteins (Bladergroen et al. 2012; Jimenez et al. 2007). 
Other studies for diagnosis of PC have been performed 
using various sample preparation or fractionation tech-
niques and resulted in sensitivities ranging from 77 % 
up to even 100 % and specificities ranging from 77 % up 
to 98 % (Deng et al. 2007; Ehmann et al. 2007; Honda 
et al. 2005; Kakisaka et al. 2007; Koopmann et al. 2004; 
Navaglia et al. 2009; Sun et al. 2007; Yu et al. 2005). 
Previously, Koomen and co-workers (Koomen et al. 
2005) reported a sensitivity of 88 % and a specificity of 
75 % using plasma purified with the so-called C18-disc, 
whereas Kojima and co-workers used serum, urine and 
plasma for analysis on a MALDI-TOF MS system in 
combination with a C18-filter plate resulting in a sen-
sitivity of 88 % and a specificity of 93 % (Kojima et al. 
2008). In this study, we have generated RPC18-based 
serum peptide profiles using an automated, high-through-
put platform aiming at discrimination of pancreatic cancer 
patients from healthy control individuals and providing 
data complementary to our previous protein profiles from 
WCX clean-up (Velstra et al. 2013). An additional advan-
tage is that peptides can be characterized more easily than 
proteins. Furthermore, we have validated the obtained 
discriminating signatures in an independent case-control 
group, and the results were evaluated with regard to rou-
tinely used imaging modalities and compared to CA19-9 
values. Finally, the structures of the most discriminating 
peptides were elucidated which could allow further inves-
tigation into their biological role in cancer progression.
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Materials and methods
Patients and serum samples
Serum samples for the calibration set were obtained 
from 49 patients with pancreatic cancer prior to surgery, 
and from 110 healthy volunteers (“controls”) over a time 
period ranging from October 2002 until December 2008 
at the Leiden University Medical Center (LUMC), in the 
Netherlands. For the validation set, serum samples were 
obtained from 39 patients and 75 healthy volunteers over 
a time period ranging from January 2009 until July 2010. 
Patients were selected candidates for curative surgery. All 
surgical specimens were examined according to routine 
histological evaluation, and the extent of the tumor spread 
was assessed by TNM (TNM Classification of Malig-
nant Tumors) classification (TNM-atlas, seventh edition, 
2009). Tumor localization, preoperative biliary drainage, 
smoking, and coincidence of diabetes were recorded. The 
tumor marker CA 19-9 was determined preoperatively 
for 46 patients using an Elecsys CA 19-9 tumor marker 
immunoassay based on the monoclonal 116-NS 19-9 
antibody (Roche). This tumor marker has a normal refer-
ence value of 0.0–37.0 U/ml (99th percentile). Informed 
consent was obtained from all subjects, and the study 
was approved by the Medical Ethical Committee of the 
LUMC. Imaging diagnostic methods (CT-scan, MRI, 
PET, EUS) were recorded, and the results were classified 
into malignant, benign or uncertain. Samples from both 
the calibration set and the validation set were collected 
and processed following a standardized high-throughput 
protocol as described (Velstra et al. 2012). All blood sam-
ples were drawn by antecubital venapuncture. The sam-
ples were collected in an 8.5 cc Serum Separator Vacu-
tainer Tube and centrifuged within maximally 4 h (de Noo 
et al. 2005). Aliquots were stored at −80 °C until further 
sample processing.
Sample processing by SPE
The isolation of peptides from serum was performed 
using RPC18-functionalized MBs (Bladergroen et al. 
2012; Jimenez et al. 2007). For this purpose, 10 μl of 
RPC18 Dynabeads was used for the analysis of 5 μl 
human serum. The activation, washing and desorption 
steps of the RPC18 beads were based on the manufactur-
ers protocol and optimized to allow implementation on 
our 96-channel Hamilton pipetting robot. Two microliter 
of eluate material (obtained from the final desorption 
step) was used for quadruplicate MALDI spotting onto a 
MALDI target plate carried out on the 96-channel pipet-
ting robot.
Mass spectrometry peptide profiling
Isotopically resolved MALDI-TOF mass spectra were 
obtained using an Ultraflex III TOF/TOF mass spectrome-
ter (Bruker Daltonics, Bremen, Germany) operating in pos-
itive reflectron mode in the m/z-range of 600–4,000. The 
spectra were externally calibrated and baseline-corrected, 
and alignment was carried out as described previously. For 
alignment, the following five peptides were selected based 
on manual inspection of all spectra, namely those at m/z-
value 1,465.8, m/z-value 1,778.1, m/z-value 1,865.2, m/z-
value 2,602.5 and m/z-value 2,931.5, with a tolerance win-
dow of 100 ppm for the m/z-value 1,465.8 peak increasing 
up to 300 ppm for the highest m/z-value. Forty-two peptide 
signals were selected and quantified for further analysis 
based on careful inspection of all profiles. Peak intensities 
were determined by summing all isotopic peaks of the 42 
selected peptides, resulting in a single intensity value for 
each peptide. MALDI-TOF profiles were exported as DAT 
(.dat) files, all containing m/z-values with corresponding 
intensities.
Data processing and statistics
First, the (.dat) files with summarized peak isotope inten-
sities were generated by in-house developed Xtractor for 
data analysis. Then, in a next step, low-quality profiles as 
a result of failed sample workup or bad MALDI spotting 
were excluded from statistical analysis (n = 6, 0.5 %). 
The mean of the available peak intensities of the quadru-
plicate spots was used for analysis. For a detailed descrip-
tion of the data processing and statistics, we refer to our 
previous work (Velstra et al. 2012). The first statistical 
analysis was based on 42 peptide signals in each profile. A 
double cross-validatory implementation of linear discrimi-
nant analysis for the calibration of a diagnostic rule using 
principal component-based shrinkage calibration on a sin-
gle (mean) spectrum per patient was performed, as previ-
ously described by our group (Mertens et al. 2006). Each 
sample was assigned to the group for which the predicted 
class probability was highest. For each analysis error rate 
(the total number of observations misclassified, expressed 
as a fraction of the number of observations (cases and con-
trols) in the sample), sensitivity, specificity and area under 
the curve (AUC) were calculated. Next, the diagnostic rule 
was implemented on the validation set, and for each analy-
sis, error, sensitivity, specificity and AUC were calculated. 
To further investigate the calibrated discriminating rule, a 
second statistical analysis on the obtained profiles was per-
formed. The original discriminating rule, based on “leav-
ing-one-item-out and finding-the-best-model” principle, 
was used to select a subset of 10 peptide peaks.




All patients were pre- or postoperatively diagnosed with 
histologically confirmed adenocarcinoma of the pancreas. 
The calibration set contained 49 preoperative pancreatic 
cancer patients (n = 23 males, n = 26 females) with a 
median age of 66 years (range 41–80). The validation set 
consisted of 39 preoperative pancreatic cancer patients (17 
males, 22 females) according to the same criteria as the cal-
ibration set with a median age of 63 years (range 38–81). 
Patient characteristics for both sets are shown in Table 1. 
The median age of the control group was 63 years (range 
44–80) and 46 years (range 21–75) for the calibration set 
(n = 50 males, n = 60 females) and validation set (n = 27 
males, n = 48 females), respectively. Thus, age of cases 
and controls was matched in the calibration set (p = 0.073); 
however, in the validation set, the age was significantly dif-
ferent for these two groups (p value of <0.001).
In both sets, the majority of the tumors (n = 75, 85 %) 
were located in the head of the pancreas. In four cases, it 
was not known where the tumor was located due to the 
presence of high infiltration. Other patient characteristics 
are demonstrated in Table 1.
Tumor differentiation was known for 36 patients (73 %) 
in the calibration set, and 28 patients (72 %) in the vali-
dation set. In total, five patients had an increased risk for 
developing PC (5.7 %). For 3 out of these 5 patients, a P16 
Leiden mutation (also annotated as a 19-base pair deletion 
of exon 2 of the CDKN2A gene) was found. One patient 
was never tested but had a 50 % risk of being a carrier 
because the mother was a carrier, while the fifth patient was 
a BRCA2 mutation carrier.
Statistical classification of serum profiles
For the whole study, 273 serum samples were pro-
cessed with RPC18 MBs and MALDI-TOF profiles 
were obtained in quadruplicate, yielding 1,092 profiles. 
Six profiles (0.5 %) were excluded from further analysis 
because of their low quality as a result of non-optimal 
MALDI spotting. Thus, for both the calibration set and 
the validation set, high-quality data were obtained for all 
samples for further statistical analysis, i.e., replicate pro-
files could be averaged for each serum sample. A typical 
example of an RPC18-profile of serum peptides is shown 
in Fig. 1. Performing linear discriminant analysis with 
double cross-validation on the calibration set resulted in 
a sensitivity of 78 %, a specificity of 91 % with an AUC 
of 0.92, and an error of 0.14. The validation data were 
predicted using the calibration classification rule. In this 
way, the promising first results could be confirmed with 
a sensitivity of 93 %, a specificity of 100 %, an AUC of 
0.98 and an error rate of 0.027. ROC curves are shown in 
Fig. 2.
Discriminating capability compared to TNM stage 
and grade
A correct classification was obtained for 37 of 49 (76 %) 
PC patients in the calibration set. In Table 1, these classifi-
cations are displayed for TNM stage and grade. For stage, 
the large majority (73 %) of the patients were diagnosed 
with early-stage PC (stages I and II). Twenty-nine (81 %) 
of these 36 patients were correctly classified, 10 out of 12 
(83 %) for stage I and 19 out of 24 (79 %) for stage II. 
Thirteen patients (4 and 9) were diagnosed with late-stage 
PC (stages III and IV). Eight (62 %) of these patients were 
correctly classified. In the validation set, a correct classifi-
cation was achieved for 37 (95 %) of 39 patients. Twenty-
eight (72 %) of the patients were operated upon in an early 
stage. Ninety-three percent of the patients with an early 
stage were correctly classified, 2 out of 4 (50 %) for stage 
I and all 24 (100 %) for stage II. All of the eleven patients 
with late-stage PC were correctly classified. In the cali-
bration set, a correct classification was obtained for eight 
patients with a grade I tumor (67 %), 10 with a grade II 
tumor (91 %) and 10 with a grade III tumor (77 %). In the 
validation set, these correct classifications were 6 (100 %), 
13 (87 %) and 7 (100 %), respectively.
Discriminating capability compared to serum biomarker 
(CA19-9)
A preoperative CA19-9 value was available for 22 patients 
in the calibration set (45 %) and for 20 patients in the 
validation set (51 %) (Table 1). Note that CA19-9 levels 
were not determined for all patients included in this study 
because of reasons discussed in the “Introduction” section 
(Goonetilleke and Siriwardena 2007). Comparisons with 
class probabilities based on RPC18 peptide signatures are 
plotted in Fig. 3. In the calibration set for 12 patients, the 
CA19-9 value was elevated, whereas in the other 10 cases, 
no increase in CA19-9 levels was diagnosed. On the con-
trary, peptide profiling resulted in a correct classification of 
all 10 “CA 19-9 negative” patients and 10 out of 12 other 
patients (83 %) This implies, in a case-based way, that pep-
tide profiling enhanced the sensitivity of detection for these 
10 cases. In the validation set, 12 patients had an elevated 
CA19-9 value of which 11 were correctly classified by pep-
tide profiling. In eight patients, CA19-9 was not increased. 
Seven of these patients were correctly classified using pep-
tide profiles.
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Table 1  Patient characteristics
* p = 0.073
^ p = 0.000
Calibration set Validation set
Cases Controls Correct classification Cases Controls Correct classification
N 49 110 39 75
Age median (min—max) 66 (41–80) 63 (44–80)* 63 (38–81) 46 (21–75)^
Male 23 50 17 27
Female 26 60 22 48
Localization
 Head 40 32 (80 %) 35 33 (94 %)
 Body 3 1 (33 %) 1 1 (100 %)
 Tail 4 4 (100 %) 1 1 (100 %)
 Unknown/other 2 1 (50 %) 2 2 (100 %)
Preoperative biliary drainage
 PTC 6 5 (83 %) 6 6 (100 %)
 Stent 24 17 (71 %) 15 15 (100 %)
 No 19 15 (79 %) 16 14 (88 %)
 Unknown 0 NA 2 2 (100 %)
Stage (TNM)
 IA 7 6 (86 %) 2 1 (50 %)
 IB 5 4 (80 %) 2 1 (50 %)
 IIA 3 3 (100 %) 3 3 (100 %)
 IIB 21 16 (76 %) 21 21 (100 %)
 III 4 2 (50 %) 2 2 (100 %)
 IV 9 6 (67 %) 9 9 (100 %)
Tumor differentiation
 Unknown (irresectable tumor) 13 (10) 8 (62 %) 11 (11) 11 (100 %)
 Grade 1 12 8 (67 %) 6 6 (100 %)
 Grade 2 11 10 (91 %) 15 13 (87 %)
 Grade 3 13 10 (77 %) 7 7 (100 %)
CA19-9
 Unknown 27 20 (74 %) 19 19 (100 %)
 Pos 12 10 (83 %) 12 11(92 %)
 Neg 10 10 (100 %) 8 7 (88 %)
Smoking
   Yes 16 13 (82 %) 10 9 (90 %)
 In the past 10 8 (80 %) 5 5 (100 %)
 No 22 15 (68 %) 24 23 (96 %)
 Unknown 1 1 (100 %) 0 NA
Diabetes
 Yes 11 9 (82 %) 11 10 (91 %)
 No 38 28 (74 %) 28 27 (96 %)
Bilirubin level
 >50 21 18 (85 %) 20 20 (100 %)
 <50 17 11 (65 %) 12 11 (92 %)
 Unknown 11 8 (73 %) 7 6 (86 %)
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Confounders
Patients that were smokers were correctly classified in the 
calibration set with 82 %. In the calibration set, 82 % of the 
patients with diabetes were found positive using peptide 
profiling versus 74 % of the patients without diabetes. For 
the validation set, these values were 91 and 96 %, respec-
tively. Patients with a bilirubin level of more than 50 were 
correctly classified in 18 out of the 21 cases (85 %) in the 
calibration set versus 11 out of the 17 patients (65 %) with 
a bilirubin level of less than 50 in the calibration set. In the 
validation set, these values were 100 and 92 %, respectively.
Discriminating capability compared to imaging methods
In Table 2, the performance of the used imaging methods 
is displayed. In 79 cases (90 %), imaging could provide a 
conclusive diagnosis. However, 9 cases (10 %) remained 
inconclusive after performing the routine diagnostic meth-
ods. In four of these cases, RPC18-based peptide profiling 
could add to correct diagnosis. For all 88 patients, a CT scan 
was performed and this resulted in 76 positives (sensitivity 
of 86 %). In 12 cases, malignancy was not diagnosed [initial 
diagnosis: benign lesion (n = 3), no consensus (n = 4) and 
no lesion seen (n = 5)]. Seven of these 12 patients (58 %) 
Fig. 1  Example of an RPC18 
profile including multiple 
overlays of the most discrimi-
nating peaks. On the x-axis, the 
m/z-values are depicted, and 
on the y-axis, the intensities 
(in arbitrary units). Peaks with 
m/z-values of 1,206.7, 1,518.9, 
1,536.9, 1,865.2, 2,271.1, 
2,602.5, 3,190.6 and 3,261.7 
were statistically evaluated 
as discriminating cases from 
controls. Profiles of cases are 
plotted in blue, profiles of con-
trols in green
Fig. 2  ROC curves of the 
calibration set and validation 
set after peak selection with 
standardization. The sensitivi-
ties are plotted in function of 
the 1-specificities for different 
cut-off points of the classifica-
tion threshold. The area under 
the ROC curve is a measure of 
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were correctly classified as malignant using peptide profil-
ing (6 with tumors in the pancreatic head, 1 in the pancre-
atic tail; 6 females, 1 male; 1 with stage IIA, 5 with stage 
IIB, 1 with stage IV). In 8 cases, an MRI was performed. In 
one patient in whom no lesion was found with MRI, peptide 
profiling also resulted in incorrect classification. Adversely, 
6 out of 7 patients with a malignant diagnosis on MRI were 
classified as positive with peptide profiling. A PET scan was 
performed for four patients. This resulted in 3 “cases,” with 
one analysis remaining inconclusive. This latter patient was 
correctly classified by peptide profiling. In 21 cases, an EUS 
was part of the diagnostic method. Six patients had an uncer-
tain or negative result, and four of these patients were cor-
rectly classified by peptide profiling.
Patients with hereditary risk
All five patients with increased risk were correctly classi-
fied with peptide profiling (100 % accuracy). For 3 cases, 
CA 19-9 values were known, of which two were elevated. 
In all 5 cases, a CT scan was performed. In 4 cases, this 
scan resulted in conclusive classification as malignant and 
the remaining CT scan resulted in an uncertain diagnosis. 
Two patients received a preoperative MRI; on both scans, a 
malignant lesion was seen. In one case, an EUS was carried 
out with inconclusive result.
Structure characterization of discriminating peptide signals
The calibrated discriminating rule was further investigated 
in an additional, second statistical analysis. The original 
discriminating rule was used to select a subset of ten pep-
tide peaks which could replicate the above-reported classifi-
cation results. This resulted in ten peaks with m/z-values of 
1,206.7, 1,518.9, 1,536.9, 1,561.9, 1,563.0, 1,865.2, 2,271.1, 
2,602.5, 3,190.6 and 3,261.7. The analyses were repeated 
using only these ten discriminating peaks, which resulted in 
a sensitivity of 80 % and a specificity of 92 % with an AUC 
of 95 % in the calibration set. For the validation set, a sen-
sitivity of 92 % and a specificity of 95 % with an AUC of 
96 % were found. The structures of the ten discriminating 
peaks (i.e., peptides) with good separation performance in 
this study were identified (Table 3), either as fragments of 
FPA-chain or FGA chain (clotting cascade) (m/z-values at 
1,206.7, 1,518.9, 1,536.9, 3,190.6 and 3,261.7—P02671), 

































37 U/mL (99th percentile)
Fig. 3  Comparison between results from RPC18-based peptide sig-
natures and CA19-9 levels
Table 2  RPC18-based peptide signature in comparison with (imag-
ing) diagnostic methods
All Correctly classified Incorrectly classified
Inconclusive imaging
 Yes 9 4 (44 %) 5 (56 %)
 No 79 70 (89 %) 9 (11 %)
CT scan pre-operative
 Yes 88 74 (84 %) 14 (16 %)
CT scan results
 Malignant 76 67 (88 %) 9 (12 %)
 Benign 3 3 (100 %) 0
 Uncertain 4 2 (50 %) 2 (50 %)
 No 5 2 (40 %) 3 (60 %)
MRI pre-operative
 Yes 8 6 (75 %) 2 (25 %)
 No 80 68 (85 %) 12 (15 %)
MRI results
 Malignant 7 6 (86 %) 1 (14 %)
 No 1 0 1 (100 %)
PET pre-operative
 Yes 4 4 (100 %) 0
 No 84 70 (83 %) 14 (17 %)
PET results
 Malignant 3 3 (100 %) 0
 Uncertain 1 1 (100 %) 0
EUS pre-operative
 Yes 19 15 (80 %) 4 (20 %)
 No 69 59 (86 %) 10 (14 %)
EUS results
 Malignant 12 10 (83 %) 2 (17 %)
 Uncertain 3 3 (100 %) 0
 No 3 1 (33 %) 2 (67 %)
 Unknown 1 1 (100 %) 0
 NA 69 59 (86 %) 10 (14 %)
 Total 88 74 (84 %) 14 (16 %)
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(m/z-values at 1,563.0 and 1,865.2—P01024), the peak at 
m/z-value 2,602.5 was identified as Factor XIIIa (clotting 
cascade) and inter-alpha-trypsin inhibitor (ITIH4) (acute 
phase reaction) (m/z-values at 2,271.1—Q14624) as over-
viewed by Tiss and co-workers and others (Erica Gianazza 
et al. 2012; Shen et al. 2010; Tiss et al. 2010). Note that 
the signals at m/z-values 1,561.9 and 1,563.0 overlap and 
can only be resolved by using ultrahigh-resolution Fourier 
transform ion cyclotron resonance (FTICR) (Nicolardi et al. 
2010).
As part of the subsequent exploratory analysis of the cal-
ibrated discriminant rule, all ten peaks were tested univari-
ately. In Table 3, the selected peaks from the multivariate 
analysis are listed together with a two-sample t test (univar-
iate assessment), the corresponding pooled estimate of the 
population standard deviation, the corresponding p value 
and the mean confidence interval. In addition, the direction 
(positive or negative) of the calibrated discriminant weight 
in the multivariate analysis (expr) is included in Table 3. 
All peaks have individual univariate significant p values 
(<0.05). It is important to note the distinction between the 
univariate and multivariate results, as the univariate meas-
ures denote the individual expression differences between 
cases and controls for each peak separately—without refer-
ence to the expression of other peaks, while the multivari-
ate results (discriminant weights) denote the conditional 
effect associated with each peak, after taking into account 
the variation in expression across the other peaks selected. 
Thus, a positive discriminant weight implies a higher case 
probability for larger values of expression at the corre-
sponding peak—after correction for the variation of other 
peaks. The reverse applies to controls. As is clear from 
Table 3, larger expression values for peaks with m/z-values 
of 1,518.9, 1,536.9, 1,865.2, 2,271.1 and 3,261.7, com-
bined with smaller expression values for peaks with m/z-
values of 1,206.7, 1,561.9, 1,563.0, 2,602.5 and 3,190.6, 
imply greater case probability, and the reverse applies for 
controls. It is important to note, however, that with respect 
to the univariate behavior for each peak separately, cases 
are consistently associated with higher expression as 
opposed to controls and across all peaks (as may also be 
seen from the t tests in Table 3 which all have the same 
sign). The multivariate behavior of the discriminant rule 
can be better understood by separating the selected peaks—
all of which have the said significant univariate effect—into 
two groups, depending on whether their calibrated discri-
minant coefficient/weight is positive or negative. As shown 
above, five of the selected peaks have a positive discrimi-
nant weight and five a negative discriminant weight. For 
each patient, the mean of the expression of peaks with a 
positive discriminant weight (MEANPOSEXPR) and the 
mean of the expression of peaks with a negative discrimi-
nant weight (MEANNEGEXPR) were calculated. As in 
the above explanation, it should be expected that samples 
showing a higher expression of MEANPOSEXPR and 
comparatively smaller expression on MEANNEGEXPR 
should be more likely to belong to the group of cases. Like-
wise, if the situation is the other way around, the probabil-
ity to belong to the control group increases. This interpre-
tation is confirmed in Fig. 4 which shows a stem and leaf 
plot in which the difference between MEANPOSEXPR 
and MEANNEGEXPR is plotted for each sample in the 
validation set. From this figure, it becomes clear that cases 
can be separated from controls based on those two sum-
marized measured expressions. To obtain final verification 
of our interpretation, the discrimination rule was repeated 
using this MEANPOSEXPR and MEANNEGEXPR sum-
marized expression only. This resulted in a sensitivity of 
80 %, a specificity of 82 % and an AUC of 90 % for the 
calibration set and a sensitivity of 90 %, a specificity of 
93 % and an AUC of 97 % for the validation set. The differ-
ences between MEANPOSEXPR and MEANNEGEXPR 
expression were calculated, and a two-sample t test was 
performed on this contrast that resulted in a t value of 9.76 
Table 3  Ten discriminating peaks with corresponding t value, p value and identification
FPA Fibrinopeptide A, ITIH4 Inter-alpha-trypsin inhibitor heavy chain H4, FGA Fibrinogen alpha
m/z-value t value SD Conditional expression p value univariate CI Identification Swiss-prot
1,206.7 3.18 3.99 − 0.0018 0.83 3.55 FPA (5–16) P02671
1,518.9 5.80 3.77 + <0.001 2.48 5.05 FPA–H2O P02671
1,536.9 5.95 3.74 + <0.001 2.57 5.12 FPA P02671
1,561.9 4.38 3.39 − <0.001 1.40 3.71 Protrombin (315–327) P00734
1,563.0 4.47 3.42 − <0.001 1.47 3.80 Complement C3f fragment (4–16) P01024
1,865.2 5.67 3.88 + <0.001 2.48 5.12 Complement C3f fragment (1–16) P01024
2,271.1 6.11 3.53 + <0.001 2.52 4.93 ITIH4 (667–687) Q14624
2,602.5 4.49 4.00 − <0.001 1.73 4.46 Factor XIIIa (14–38) P00488
3,190.6 2.89 4.03 − 0.0044 0.63 3.38 FGA (576–603) P02671
3,261.7 3.63 4.26 + 0.00039 1.21 4.12 FGA chain (576–604) P02671
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and a p value of <0.0001 in the calibration set and a t value 
of 13.87 with a p value of <0.0001 in the validation set.
Discussion
Clinical proteomics approaches have emerged as a power-
ful tool for the diagnosis of PC and application in surveil-
lance programs (Cecconi et al. 2011; Chen et al. 2009; Liu 
et al. 2009; Pawa et al. 2010; Zapico-Muniz et al. 2010). 
In this study, a serum peptide signature is presented for the 
detection of pancreatic cancer. Serum fractionation was 
performed with RPC18-MBs, followed by high-resolution 
MS profiling, in order to develop a discriminating peptide 
profile for patients with PC, resulting in a high sensitivity 
of 76 % (95 %) and a specificity of 91 % (100 %) in the 
calibration and validation sets, respectively. We found an 
enhanced sensitivity and specificity compared to our pre-
vious reported classification results for (small) proteins 
(molecular weights 3–12 kDa) obtained from a WCX-SPE 
method, which were 74 and 91 % for the validation set 
(Velstra et al. 2013). Note that the study population mostly 
consisted of patients with early-stage PC. Early detection 
of PC may result in a higher number of patients that might 
benefit from a pancreaticoduodenectomy and, moreover, 
in increased survival times. The sensitivity value for the 
entire set of PC patients obtained from imaging CT scans 
was 86 %, and from MRI, PET and EUS 75, 75 and 60 %, 
respectively. Moreover, the MS-based profiling results were 
compared to CA19-9 readouts, with an overall sensitivity 
of 65 %. Previously, Goonetilleke and co-workers reviewed 
CA19-9 as a diagnostic serum marker for PC and found 
a median sensitivity of 79 % and a specificity of 82 % 
(Goonetilleke and Siriwardena 2007). In the current study, 
out of 24 patients with a positive CA19-9 test, 21 patients 
were classified as “cases” on the basis of peptide profiling 
results. Out of 18 patients with a negative CA19-9 value, 
17 were classified as “cases” based on peptide signatures, 
thus implying the beneficial aspects of the here presented 
methodology.
In principle, with current MS-based proteomics 
approaches, any protein can be detected, but the “real-
life” sensitivity of the method is strongly affected by the 
nature of the sample. Biological samples are typically char-
acterized by a wide range of protein abundances (for pro-
teins in blood, this is more than 10 orders of magnitude), 
and no analytical method is available that can tackle such 
dynamic range in one go. Sample fractionation at least in 
part overcomes this problem and allows a more in-depth 
analysis of the proteome (Nilsson et al. 2010). In the cur-
rent study, RPC18-MBs with specific binding character-
istics were used. Such paramagnetic beads can well be 
implemented in a robotic platform for fully automated 
use, thus ensuring the control of each step in the extrac-
tion protocol and minimizing technical variability (Jime-
nez et al. 2007). Previously, profiles studies were criticized 
because protein identities were not reported with these 
“black-box” approaches (Nilsson et al. 2010). As a conse-
quence, emphasis in biomarker research has moved from 
discovery to structure characterization. We therefore per-
formed additional statistical analyses to further investigate 
the discriminative rule and to give insight into the identity 
of the peaks. The classification of PC patient and control 
samples could be validated even after summarizing the data 
in the mean of the expression of peaks with a positive dis-
criminant weight (MEANPOSEXPR) and the mean of the 
expression of peaks with a negative discriminant weight 
(MEANNEGEXPR). Taking the mean of the profiles with 
the same direction of expression is only one of the meth-
ods that could be used to explore this type of data. It seems 
logical to first determine the diagnostic power of candidate 
markers before performing identification studies. Never-
theless, characterization of the discriminating peptides has 
become a crucial element to allow further investigations 
into their biological role in disease mechanisms. It should 
be noted, however, that identification of peptide- or pro-
tein signals in a profile is not straightforward. Until now, 
most reported identifications of serum peptides in profiles 
have been based on SELDI enrichment chips [i.e., Immo-
bilized Metal Affinity Capture (IMAC) (Koopmann et al. 
2004)] or on SPE-based (RPC18) procedures (Koomen 
et al. 2005; Tiss et al. 2010). Recently, prognostic protein 
markers of resectable PC were identified by applying MS-
based proteomic analysis on tissues (Takadate et al. 2013). 
The structures of the 10 discriminating peaks, which in this 
study showed good separation performance, have been elu-
cidated previously (Table 3). The identified peptides were 
found to originate from proteins that relate to the clotting 
cascade, or the immunologic response of the acute phase 
reaction. The clinical value of these peptides requires 
Fig. 4  Stem-and-leave plot of the validation data based on MEAN-
POSEXPR–MEANNEGEXPR. The blue circles correspond to the 
cases, the red crosses with the controls. Items with the same expres-
sion were plotted vertically. The controls are more located on the left 
of the horizontal axis; the cases are more located on the right
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further investigation. It is known that this profiling method 
primarily results in the detection of high-abundant proteins 
and their proteolytic fragments. Fractionation techniques 
remain crucial for obtaining information on low-abundant 
peptides and proteins. The here identified proteins could 
be a result of pancreatitis that accompanies PC develop-
ment. A very important next step is to analyze the serum 
proteomic profile in a group of patients with chronic pan-
creatitis. Any reliable comparison of PC markers requires 
the use of large number of pancreatitis controls, and we are 
currently collecting samples.
The most practical and cost-effective clinical advan-
tage would be achieved if patients with an elevated risk 
to develop pancreatic cancer could benefit from a highly 
sensitive and specific peptide- or protein profiling serum 
test (Ghatnekar et al. 2013). With the current peptide-pro-
filing technique, it was possible to correctly classify all 
five patients with an increased risk for PC. Three of these 
patients were carrier of a p16-Leiden mutation. A simple 
screening test to be performed between regular screening 
moments with MRI might be beneficial for these patients. 
However, our MS profile has not been tested for such a 
group with hereditary higher risk. We are now analyzing 
retrospective series and in addition collect serum sam-
ples of individuals belonging to this high-risk group dur-
ing surveillance. For similar reasons, other risk factors for 
developing PC such as diabetes and smoking habits will be 
considered in future analyses. This study can be seen as a 
second step, following our first step presented earlier (Vel-
stra et al. 2013), in which we have improved the cleaning 
up procedures. Further technical improvements are ongo-
ing, with promising preliminary results.
In conclusion, the applied MS approach allowed rapid, 
accurate and reproducible analysis of serum peptides to 
obtain signatures with a high sensitivity at relatively low 
cost. Automation ensures a robust peptide isolation pro-
tocol. This study demonstrates the potential of a serum 
peptide signature as a diagnostic method for the detection 
of pancreatic cancer. This application of this method can 
be complementary to currently used diagnostic methods 
in the clinic. Such a test would be beneficial for patients 
with an inherited risk for PC by allowing more frequent 
screening.
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